Description

Avastin (bevacizumab) concentrate for infusions 100 mg/4 ml. №1 vial

Ingredients

Active ingredient: Bevacizumab. Inactive ingredients may include sodium chloride, polysorbate 20, and water for injection.

Dosage

Dosage: The recommended dose of Avastin is 5 mg/kg of body weight administered as an intravenous infusion every 2 weeks.

Indications

Indications: Avastin is indicated for the treatment of various cancers including metastatic colorectal cancer, non-small cell lung cancer, and glioblastoma.

Contraindications

Contraindications: Avastin is contraindicated in patients with a history of gastrointestinal perforation, wound healing complications, or severe bleeding.

Directions

Administration: Avastin should be administered by a healthcare professional experienced in the use of anticancer therapies. The infusion should be given over a period of 90 minutes.

Scientific Evidence

Avastin works by inhibiting the formation of new blood vessels, a process known as angiogenesis, which is crucial for tumor growth and metastasis. Several clinical trials have demonstrated the efficacy of Avastin in combination with chemotherapy in various types of cancer. For example, a study published in the New England Journal of Medicine showed that Avastin, when added to standard chemotherapy, significantly prolonged progression-free survival in patients with metastatic colorectal cancer.

Additional Information

Avastin may cause serious side effects including gastrointestinal perforation, wound healing complications, and hypertension. Patients should be closely monitored during treatment. It is important to discuss the risks and benefits of Avastin therapy with a healthcare provider.

Pharmacological Effects: Avastin’s mechanism of action involves binding to vascular endothelial growth factor (VEGF) and inhibiting its interaction with receptors on the surface of endothelial cells. By blocking VEGF, Avastin disrupts the signaling pathways that promote angiogenesis, thereby limiting the blood supply to tumors and inhibiting their growth.

Clinical Trials: Clinical trials have shown that Avastin, when used in combination with chemotherapy, can improve outcomes in patients with various types of cancer. For example, a study published in the Journal of Clinical Oncology demonstrated that Avastin, in combination with paclitaxel, significantly increased overall survival in patients with metastatic breast cancer compared to chemotherapy alone.